Allogene Therapeutics (ALLO) Institutional Ownership
13F filers reported holding 87.8% of Allogene Therapeutics (ALLO) shares as of Sep 30, 2026, across 197 filers.
- Held by 13F filers
- 87.8%
- Sep 30, 2026
- 13F filers
- 197
- quarter ended Sep 30, 2026
- 13F value
- $487.7M
- 304.1M shares
- Quarter's fund flow
- Mild distribution
- 25 new · 31 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 21, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 36,342 | $1.34 | ↗ |
| Aug 21, 2026 | Douglas Earl Martin | SVP, General Counsel | Disposed · Open-market sale | 29,697 | $2.12 | ↗ |
| Jul 1, 2026 | Roberts Zachary | President and CEO | Acquired · Grant / award | 134,530Restricted Stock Unit | — | ↗ |
| Jul 1, 2026 | Roberts Zachary | President and CEO | Acquired · Grant / award | 476,190Stock Option (Right to buy) | — | ↗ |
| Jun 18, 2026 | Barrett Elizabeth A. | director | Acquired · Grant / award | 95,400Restricted Stock Unit | — | ↗ |
| Jun 18, 2026 | MESSEMER DEBORAH M. | director | Acquired · Grant / award | 95,400Restricted Stock Unit | — | ↗ |
| Jun 18, 2026 | Mayo Stephen | director | Acquired · Grant / award | 144,400Stock Option (Right to buy) | — | ↗ |
| Jun 18, 2026 | WITTE OWEN N. | director | Acquired · Grant / award | 95,400Restricted Stock Unit | — | ↗ |
| Jun 18, 2026 | Humer Franz B | director | Acquired · Grant / award | 95,400Restricted Stock Unit | — | ↗ |
| Jun 18, 2026 | Kazam Joshua A | director | Acquired · Option exercise | 47,700 | — | ↗ |
| Jun 18, 2026 | Kazam Joshua A | director | Disposed · Option exercise | 47,700Restricted Stock Unit | — | ↗ |
| Jun 18, 2026 | Kazam Joshua A | director | Acquired · Grant / award | 95,400Restricted Stock Unit | — | ↗ |
| Jun 18, 2026 | SATO VICKI L | director | Acquired · Grant / award | 95,400Restricted Stock Unit | — | ↗ |
| Apr 21, 2026 | Yoshiyama Annie | SVP, Finance | Disposed · Open-market sale | 9,586 | $2.31 | ↗ |
| Mar 31, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Disposed · Open-market sale | 2,867 | $2.50 | ↗ |
| Mar 16, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Disposed · Open-market sale | 4,835 | $2.47 | ↗ |
| Mar 16, 2026 | Chang David D | President and CEO | Disposed · Open-market sale | 47,763 | $2.47 | ↗ |
| Mar 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Disposed · Open-market sale | 7,132 | $2.60 | ↗ |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Disposed · Open-market sale | 7,549 | $1.73 | ↗ |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Acquired · Grant / award | 373,757Stock Option (Right to buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 50 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Allogene Therapeutics do institutions hold?
13F filers reported holding 87.8% of Allogene Therapeutics' shares as of Sep 30, 2026, across 197 filers.
How many 13F filers hold Allogene Therapeutics?
Allogene Therapeutics was held by 197 13F filers as of Sep 30, 2026.
Not investment advice.

